Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction,
leading to MET internalization and degradation.
Clinical Use
A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and
in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.
